MedTrace Logo

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

NCT00442533 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-04-03

No results posted yet for this study

Summary

The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.

Conditions

Interventions

DRUG

Indium-111 pentetreotide

4 cycles of 500 mCi treatments every 10-12 weeks

Sponsors & Collaborators

  • Excel Diagnostic Imaging Clinics

    collaborator UNKNOWN

  • Radiomedix, Inc.

    collaborator INDUSTRY

  • CHI St. Luke's Health, Texas

    collaborator OTHER

  • Radio Isotope Therapy of America

    lead OTHER

Principal Investigators

  • Ebrahim Delpassand, M.D. · RITA Foundation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2014-08-30
Completion
2015-12-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00442533 on ClinicalTrials.gov